Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17699252 | 0.88 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL525363 | 0.87 | FABP5 (0.49) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4600771 | 0.87 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL524690 | 0.86 | FABP5 (0.48) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL7401416 | 0.85 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL1409924 | 0.83 | FABP5 (0.43) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601669 | 0.82 | FABP5 (0.50) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL1157426 | 0.80 | FABP5 (0.47) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL4601031 | 0.80 | FABP5 (0.45) | FABP5FABP7KMT2AEPHX2CA1 | |
| SCHEMBL18614244 | 0.78 | FABP5 (0.46) | FABP5FABP7KMT2AEPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605409-A2 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-4208466-B1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2025-06-11 | — | — | EP | disclosed |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | ZYMEWORKS BC INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| US-20240218021-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024086814-A2 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | Technische Universität Darmstadt (DE) | 2023-12-05 | — | — | US | disclosed |
| EP-4208466-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2023-07-12 | — | — | EP | disclosed |
| US-20230212185-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2023-01-26 | — | — | US | disclosed |
| WO-2022049005-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2022-03-10 | — | — | WO | disclosed |
| WO-2002036616-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| WO-2002036807-A2 | COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS | DIADEXUS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020048763-A1 | Human genome-derived single exon nucleic acid probes useful for gene expression analysis | AMERSHAM PLC (GB) | 2002-04-25 | — | — | US | disclosed |
| US-20020048800-A1 | Myosin-like gene expressed in human heart and muscle | GE HEALTHCARE LIMITED (GB) | 2002-04-25 | — | — | US | disclosed |
| WO-2002026818-A2 | HUMAN NEDD-1 | AEOMICA, INT. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002024750-A2 | HUMAN KIDNEY TUMOR OVEREXPRESSED MEMBRANE PROTEIN 1 | AEOMICA, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| CN-1051769-C | Peptides | NOVATIS INC (CH) | 2000-04-26 | — | — | CN | disclosed |
| EP-0672057-A1 | ANALOGS OF PTH | Novartis AG (CH) | 1995-09-20 | — | — | EP | disclosed |
| CN-1099801-A | Peptides | SANDOZ LTD (CH) | 1995-03-08 | — | — | CN | disclosed |
| WO-1994002510-A2 | ANALOGS OF PTH | SANDOZ LTD. (CH) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022534-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | ENPP2, TPX2, PRXL2A | FABP5 3671/4885FABP7 3739/4885KMT2A 1651/4885 |
| US-20230212185-A1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | FKBP1B, FKBP5, FKBP1A | FABP5 87/4885FABP7 20/4885KMT2A 1826/4885 |
| US-20240218021-A1 | CYCLIN INHIBITORS | CCNI, CCNC, CDK2 | FABP5 3119/4885FABP7 3683/4885KMT2A 1479/4885 |
| US-11834463-B2 | High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders | FKBP1B, FKBP5, FKBP1A | FABP5 87/4885FABP7 20/4885KMT2A 1826/4885 |
| US-20240376154-A1 | BIS-INTERCALATING PEPTIDES, CONJUGATES AND METHODS OF USE | PCNA, POLI, VIP | FABP5 1275/4885FABP7 1644/4885KMT2A 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.